Dapagliflozin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heart Failure With Reduced Ejection Fraction (HFrEF)

Conditions

Heart Failure With Reduced Ejection Fraction (HFrEF)

Trial Timeline

Apr 9, 2019 → Mar 7, 2020

NCT ID

NCT03877237

About Dapagliflozin

Dapagliflozin is a phase 3 stage product being developed by AstraZeneca for Heart Failure With Reduced Ejection Fraction (HFrEF). The current trial status is completed. This product is registered under clinical trial identifier NCT03877237. Target conditions include Heart Failure With Reduced Ejection Fraction (HFrEF).

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure With Reduced Ejection Fraction (HFrEF) were approved

Approved (20) Terminated (2) Active (0)

✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved

✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved

✅ConivaptanAstellas PharmaApproved

✅RegadenosonAstellas PharmaApproved

✅Regadenoson + GadoliniumAstellas PharmaApproved

✅regadenosonAstellas PharmaApproved

✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06610526	Approved	Active	Aug 23, 2024	May 31, 2027	Chronic Kidney Disease
NCT05250011	Pre-clinical	Completed	Apr 19, 2022	Apr 15, 2024	Heart Failure, Reduced Ejection Fraction
NCT03877237	Phase 3	Completed	Apr 9, 2019	Mar 7, 2020	Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT03877224	Phase 3	Completed	Apr 4, 2019	Jul 9, 2020	Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT03782259	Approved	Completed	Feb 26, 2019	Nov 16, 2022	Type 2 Diabetes Mellitus
NCT03338855	Approved	Completed	Mar 5, 2018	Nov 4, 2019	Diabetes Mellitus, Type 2
NCT03152084	Approved	Terminated	Jul 12, 2017	Mar 20, 2020	Diabetes Mellitus, Type 2
NCT02585804	Approved	Completed	Sep 1, 2015	Apr 24, 2017	Focal Segmental Glomerulosclerosis
NCT02460978	Phase 3	Completed	Jul 8, 2015	Apr 18, 2018	Type 1 Diabetes Mellitus
NCT02420392	Pre-clinical	Completed	Feb 1, 2015	Apr 1, 2016	Diabetes Mellitus, Type 2
NCT01294436	Phase 3	Completed	Feb 1, 2011	Sep 1, 2012	Type2 Diabetes
NCT01165268	Phase 1	Completed	Aug 1, 2010	Dec 1, 2010	Type 2 Diabetes Mellitus
NCT01055652	Phase 1	Completed	Jan 1, 2010	Apr 1, 2010	Type 2 Diabetes Mellitus
NCT00908271	Phase 1	Completed	Jul 1, 2009	Aug 1, 2009	Type 2 Diabetes Mellitus
NCT00726505	Phase 1	Terminated	Jun 1, 2009	Aug 1, 2009	Diabetes, NOS
NCT00554450	Phase 1	Completed	Mar 1, 2006	Oct 1, 2008	Diabetes Mellitus, Type 2

Competing Products

20 competing products in Heart Failure With Reduced Ejection Fraction (HFrEF)

See all competitors

Product	Company	Stage	Hype Score
mRNA-0184	Moderna	Phase 1	0
IV diuretic	Nuwellis	Pre-clinical	16
IV Loop Diuretics	Nuwellis	Pre-clinical	23
Stepped pharmacologic care	Nuwellis	Phase 3	30
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	8
TRV120027 + Normal Saline	Trevena	Phase 1	19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	25
TRV120027 + Placebo	Trevena	Phase 1/2	22
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	25
INXN-4001	Precigen	Phase 1	23
LY3461767 + Placebo	Eli Lilly	Phase 1	29
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	43
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	32
Olmesartan	Daiichi Sankyo	Phase 3	40
Carperitide + Placebo	Daiichi Sankyo	Phase 2	35
Edoxaban	Daiichi Sankyo	Pre-clinical	22
Regadenoson	Astellas Pharma	Phase 1	29
Advagraf + Prograf	Astellas Pharma	Phase 2	35